Effect of disease-modifying drugs on cortical lesions and atrophy in relapsing-remitting multiple sclerosis

Multiple Sclerosis Journal

Volumn 18, Issue 4, 2012, Pages 418-424

  Calabrese, M ^a   Bernardi, V ^a   Atzori, M ^a   Mattisi, I ^a   Favaretto, A ^a   Rinaldi, F ^a   Perini, P ^a   Gallo, P ^a  

^a UNIVERSITY HOSPITAL OF PADOVA   (Italy)

Author keywords

cortical lesions; disease modifying drugs; double inversion recovery; grey matter atrophy; magnetic resonance imaging; multiple sclerosis

Indexed keywords

BETA1A INTERFERON; GLATIRAMER;

ADULT; ARTICLE; BRAIN CORTEX ATROPHY; BRAIN CORTEX LESION; CLINICAL EXAMINATION; CONTROLLED STUDY; DRUG EFFECT; FEMALE; GRAY MATTER; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 80054944461     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458510394702     Document Type: Article

References (43)

1. Goodin DS, Frohman EM, Garmany GP, Halper J, Likosky WH, Lublin FD, et al. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology. 2002 ; 58: 169-178
2. Interferon beta-1b in the treatment of multiple sclerosis: Final outcome of the randomized controlled trial. Neurology. 1995 ; 45: 1277-1285
3. Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol. 1996 ; 39: 285-294
4. Li DK, Paty DW. Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon-beta1a in relapsing-remitting multiple sclerosis. Ann Neurol. 1999 ; 46: 197-206
5. Paty DW, Li DK. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group. Neurology. 1993 ; 43: 662-667
6. PRISMS-4: long-term efficacy of interferon-beta-1a in relapsing MS. Neurology. 2001 ; 56: 1628-1636
7. Comi G, Filippi M, Barkhof F, Durelli L, Edan G, Fernández O, et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet. 2001 ; 357: 1576-1582
8. Jacobs LD, Beck RW, Simon JH, Kinkel RP, Brownscheidle CM, Murray TJ, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med. 2000 ; 343: 898-904
9. Kappos L, Polman CH, Freedman MS, Edan G, Hartung HP, Miller DH, et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology. 2006 ; 67: 1242-1249
10. Kappos L, Freedman MS, Polman CH, Edan G, Hartung HP, Miller DH, et al. Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet. 2007 ; 370: 389-397
11. Comi G, Martinelli V, Rodegher M, Moiola L, Bajenaru O, Carra A, et al. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet. 2009 ; 374: 1503-1511
12. Barkhof F. The clinico-radiological paradox in multiple sclerosis revisited. Curr Opin Neurol. 2002 ; 15: 239-245
13. Bo L, Vedeler CA, Nyland HI, Trapp BD, Mork SJ. Subpial demyelination in the cerebral cortex of multiple sclerosis patients. J Neuropathol Exp Neurol. 2003 ; 62: 723-732
14. Geurts JJ, Bö L, Roosendaal SD, Hazes T, Daniëls R, Barkhof F, et al. Extensive hippocampal demyelination in multiple sclerosis. J Neuropathol Exp Neurol. 2007 ; 66: 819-827
15. Kutzelnigg A, Lucchinetti CF, Stadelmann C, Brück W, Rauschka H, Bergmann M, et al. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain. 2005 ; 128: 2705-2712
16. Vercellino M, Plano F, Votta B, Mutani R, Giordana MT, Cavalla P. Grey matter pathology in multiple sclerosis. J Neuropathol Exp Neurol. 2005 ; 64: 1101-1107
17. Calabrese M, De Stefano N, Atzori M, Bernardi V, Mattisi I, Barachino L, et al. Detection of cortical inflammatory lesions by double inversion recovery magnetic resonance imaging in patients with multiple sclerosis. Arch Neurol. 2007 ; 64: 1416-1422
18. Calabrese M, De Stefano N, Atzori M, Bernardi V, Mattisi I, Barachino L, et al. Extensive cortical inflammation is associated with epilepsy in multiple sclerosis. J Neurol. 2008 ; 255: 581-586
19. Calabrese M, Gallo P. Magnetic resonance evidence of cortical onset of multiple sclerosis. Mult Scler. 2009 ; 15: 933-941
20. Calabrese M, Filippi M, Rovaris M, Bernardi V, Atzori M, Mattisi I, et al. Evidence for relative cortical sparing in benign multiple sclerosis: a longitudinal magnetic resonance imaging study. Mult Scler. 2009 ; 15: 36-41
21. Calabrese M, Rocca MA, Atzori M, Mattisi I, Bernardi V, Favaretto A, et al. Cortical lesions in primary progressive multiple sclerosis: a 2-year longitudinal MR study. Neurology. 2009 ; 72: 1330-1336
22. Calabrese M, Agosta F, Rinaldi F, Mattisi I, Grossi P, Favaretto A, et al. Cortical lesions and atrophy associated with cognitive impairment in relapsing-remitting multiple sclerosis. Arch Neurol. 2009 ; 66: 1144-1150
23. Kutzelnigg A, Lassmann H. Cortical demyelination in multiple sclerosis: a substrate for cognitive deficits?. J Neurol Sci. 2006 ; 245: 123-126
24. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol. 2001 ; 50: 121-127
25. Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol. 2005 ; 58: 840-846
26. Miller DH, Barkhof F, Berry I, Kappos L, Scotti G, Thompson AJ. Magnetic resonance imaging in monitoring the treatment of multiple sclerosis: concerted action guidelines. J Neurol Neurosurg Psychiatry. 1991 ; 54: 683-688
27. Calabrese M, Rocca MA, Atzori M, Mattisi I, Favaretto A, Perini P, et al. A 3-year magnetic resonance imaging study of cortical lesions in relapse-onset multiple sclerosis. Ann Neurol. 2010 ; 67: 376-383
28. Tukey JW. Comparing individual means in the analysis of variance. Biometrics. 1949 ; 5: 99-114
29. Kappos L, Radue EW, O'Connor P, Polman C, Hohlfeld R, Calabresi P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010 ; 362: 387-401
30. Giovannoni G, Comi G, Cook S, Rammohan K, Rieckmann P, Soelberg Sørensen P, et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med. 2010 ; 362: 416-426
31. Wynn D, Kaufman M, Montalban X, Vollmer T, Simon J, Elkins J, et al. Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta. Lancet Neurol. 2010 ; 9: 381-390
32. Mikol DD, Barkhof F, Chang P, Coyle PK, Jeffery DR, Schwid SR, et al. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the Rebif vs Glatiramer Acetate in Relapsing MS Disease (REGARD) study): a multicentre, randomised, parallel, open-label trial. Lancet Neurol. 2008 ; 7: 903-914
33. Schwid SR, Panitch HS. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis. Clin Ther. 2007 ; 29: 2031-2048
34. O'Connor P, Filippi M, Arnason B, Comi G, Cook S, Goodin D, et al. 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol. 2009 ; 8: 889-897
35. Audoin B, Davies GR, Finisku L, Chard DT, Thompson AJ, Miller DH. Localization of grey matter atrophy in early RRMS: A longitudinal study. J Neurol. 2006 ; 253: 1495-1501
36. Chen JT, Narayanan S, Collins DL, Smith SM, Matthews PM, Arnold DL. Relating neocortical pathology to disability progression in multiple sclerosis using MRI. NeuroImage. 2004 ; 23: 1168-1175
37. Pagani E, Rocca MA, Gallo A, Rovaris M, Martinelli V, Comi G, et al. Regional brain atrophy evolves differently in patients with multiple sclerosis according to clinical phenotype. Am J Neuroradiol. 2005 ; 26: 341-346
38. Rudick RA, Fisher E. Brain atrophy as an outcome measure for multiple sclerosis clinical trials: a "no-brainer"?. Neurology. 2009 ; 72: 586-587
39. Zivadinov R, Sepcic J, Nasuelli D, De Masi R, Bragadin LM, Tommasi MA, et al. A longitudinal study of brain atrophy and cognitive disturbances in the early phase of relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry. 2001 ; 70: 773-780
40. Pirko I, Lucchinetti CF, Sriram S, Bakshi R. Gray matter involvement in multiple sclerosis. Neurology. 2007 ; 68: 634-642
41. Tiberio M, Chard DT, Altmann DR, Davies G, Griffin CM, Rashid W, et al. Gray and white matter volume changes in early RRMS: a 2-year longitudinal study. Neurology. 2005 ; 64: 1001-1007
42. Bermel RA, Bakshi R. The measurement and clinical relevance of brain atrophy in multiple sclerosis. Lancet Neurol. 2006 ; 5: 158-170
43. Roosendaal SD, Moraal B, Pouwels PJ, Vrenken H, Castelijns JA, Barkhof F, et al. Accumulation of cortical lesions in MS: relation with cognitive impairment. Mult Scler. 2009 ; 15: 708-714